The Longitudinal Monitoring Program: A Robust Approach to Drug Testing

As doping evolves and becomes increasingly complex, so do the challenges in detecting it. In additional to developing new tests to detect performance-enhancing drugs, ADSI’s chief science officer, Don Catlin, M.D., was an early advocate of drug-testing programs that monitor various biomarkers for indications of doping. By analyzing competitors’ key markers in blood and urine, drug testers get an idea if banned substances have been used or not. Coupling such monitoring with the detection of specific substances through traditional testing offers the most robust approach.

Many have gone on to create such programs based on their own needs, constituents, restrictions and other considerations. At ADSI, we are proud to offer our own program, called the Longitudinal Monitoring Program, which has many factors that make it one of the best drug-testing programs.

ADSI’s core program involves the collection of blood and urine samples for analysis of a number of important biological markers, such as hemoglobin, hematocrit, and testosterone. We also test for the presence of specific banned substances such as EPO and related blood boosters, steroids and more. Results are reviewed by our experts for any patterns or signs of doping. We use the services of International Doping Tests & Management (IDTM) to conduct our collections according to international standards and procedures. Depending on your needs, we can customize the options to fit your purpose and budget. Although we recommend our gold-standard program, our other options can provide effective drug-testing solutions as well.

In recent years, ADSI has provided its Longitudinal Monitoring Program to Columbia and Garmin-Slipstream Professional Cycling teams. These athletes and their managers have demonstrated a personal dedication to fighting doping in their sport, and we are pleased to work with them in that important pursuit.